Ajinomoto Co.

Ajinomoto applies its core fermentation and amino acid production technology across six commercial verticals: amino acids sold as pharmaceutical-grade raw materials, animal nutrition feed-grade supplements, food and beverage ingredient solutions, medical nutrition for chronic conditions, stem cell growth media for regenerative medicine, and specialty chemicals for personal care. The North American subsidiary Ajinomoto Health & Nutrition acts as the B2B channel for pharma, biotech, and food manufacturer ingredients, while subsidiaries like Forge Biologics use amino acid-derived cell culture media to manufacture gene therapies for third-party clients (per the firm, 2024).

Yes — through its wholly owned subsidiary Forge Biologics, headquartered in Grove City, Ohio, Ajinomoto operates a contract development and manufacturing organization (CDMO) specializing in adeno-associated virus (AAV) gene therapy production. Forge's 200,000-square-foot facility includes 20 cGMP suites and offers end-to-end plasmid, viral vector, and fill-finish services. Ajinomoto acquired Forge in 2022, converting its position from an amino acid supplier to a controlling stakeholder in cell and gene therapy manufacturing infrastructure (per Ajinomoto Co., 2022).

Ajinomoto Health & Nutrition North America, Inc. is a wholly owned subsidiary of Ajinomoto Co., Inc., the publicly traded entity on the Tokyo Stock Exchange. Within the North American network, Ajinomoto Health & Nutrition functions as the B2B ingredient, medical nutrition, and bioscience arm — distinct from consumer-facing frozen foods operations run by a separate subsidiary, Ajinomoto Foods North America. This structure segments regulated pharma and biotech supply contracts from branded consumer goods under the same ultimate parent entity (per the firm, 2024).

Ajinomoto Cambrooke, based in Ayer, Massachusetts, is a wholly owned subsidiary focused on medical foods for inborn errors of metabolism — including phenylketonuria (PKU) — as well as ketogenic medical diets for epilepsy and allergen-free nutrition. It was founded as Cambrooke Therapeutics in 2000 by Lynn and David Paolella after their son's PKU diagnosis, and was subsequently acquired by Ajinomoto to anchor its medical nutrition vertical. The subsidiary operates its own customer service and manufacturing logistics distinct from Ajinomoto Health & Nutrition's general amino acid supply business (per the firm, 2024).

In 2023, Ajinomoto Health & Nutrition became a Gold Sponsor of LabCentral, a Cambridge, Massachusetts-based biotech incubator that houses over 70 early-stage life science companies. The sponsorship provides direct access to therapeutic developers that could become customers for Ajinomoto's pharmaceutical-grade amino acid ingredients and cell culture media — effectively creating a pipeline-generation channel for its bioscience supply division without requiring the group to invest venture capital (per the firm, October 2023).